CR20140503A - Compuestos heterociclicos y sus usos - Google Patents

Compuestos heterociclicos y sus usos

Info

Publication number
CR20140503A
CR20140503A CR20140503A CR20140503A CR20140503A CR 20140503 A CR20140503 A CR 20140503A CR 20140503 A CR20140503 A CR 20140503A CR 20140503 A CR20140503 A CR 20140503A CR 20140503 A CR20140503 A CR 20140503A
Authority
CR
Costa Rica
Prior art keywords
inflammatory
disorders
bladder
arthritis
diseases
Prior art date
Application number
CR20140503A
Other languages
English (en)
Inventor
Minna Hue Thanh Bui
Timothy D Cushing
Lopez De Turiso Felix Gonzalez
Xiaolin Hao
Brian Lucas
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20140503A publication Critical patent/CR20140503A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen heteroarilo bicíclicos sustituidos y composiciones que los contienen, para el tratamiento de inflamación general, artritis, enfermedades reumáticas, osteoartritis, trastornos inflamatorios del intestino, trastornos inflamatorios de los ojos, trastornos inflamatorios de la vejiga o vejiga inestable, psoriasis, complicaciones de la piel con componentes inflamatorios, afecciones inflamatorias crónicas, incluyendo pero no restringido a enfermedades autoinmunitarias tales como lupus eritematoso sistémico (SLE), miastenia grave, artritis reumatoide, encefalomielitis aguda diseminada, púrpura trombocitopénica idiopática, esclerosis múltiple, síndrome de Sjoegren y anemia hemolítica autoinmunitaria, afecciones alérgicas incluyendo todas las formas de hipersensibilidad.
CR20140503A 2012-04-04 2014-10-30 Compuestos heterociclicos y sus usos CR20140503A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620270P 2012-04-04 2012-04-04
PCT/US2013/035203 WO2013152150A1 (en) 2012-04-04 2013-04-04 Heterocyclic compounds and their uses

Publications (1)

Publication Number Publication Date
CR20140503A true CR20140503A (es) 2015-03-06

Family

ID=48142975

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140503A CR20140503A (es) 2012-04-04 2014-10-30 Compuestos heterociclicos y sus usos

Country Status (31)

Country Link
US (2) US8716290B2 (es)
EP (1) EP2834231B1 (es)
JP (1) JP2015512451A (es)
KR (1) KR20140139547A (es)
CN (1) CN104395305A (es)
AP (1) AP3611A (es)
AU (1) AU2013243506A1 (es)
CA (1) CA2869413A1 (es)
CL (1) CL2014002686A1 (es)
CO (1) CO7091181A2 (es)
CR (1) CR20140503A (es)
CY (1) CY1117487T1 (es)
DK (1) DK2834231T3 (es)
EA (1) EA201491823A1 (es)
ES (1) ES2577109T3 (es)
HR (1) HRP20160352T1 (es)
HU (1) HUE028762T2 (es)
IL (1) IL234822A0 (es)
MA (1) MA37472A1 (es)
ME (1) ME02473B (es)
MX (1) MX2014011970A (es)
PE (1) PE20142457A1 (es)
PH (1) PH12014502246A1 (es)
PL (1) PL2834231T3 (es)
RS (1) RS54716B1 (es)
SG (1) SG11201406316VA (es)
SI (1) SI2834231T1 (es)
SM (1) SMT201600211B (es)
TN (1) TN2014000412A1 (es)
WO (1) WO2013152150A1 (es)
ZA (1) ZA201407037B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068343A1 (en) * 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
WO2013152150A1 (en) * 2012-04-04 2013-10-10 Amgen Inc. Heterocyclic compounds and their uses
TW201625621A (zh) 2014-05-06 2016-07-16 艾恩傑股份有限公司 Pi3k抑制劑之形式
EA201692557A1 (ru) 2014-07-04 2017-05-31 Люпин Лимитед Хинолизиноновые производные в качестве ингибиторов pi3k
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
EP3400227B1 (en) * 2016-03-05 2021-03-31 Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TWI853009B (zh) * 2019-03-29 2024-08-21 瑞士商先正達農作物保護公司 殺有害生物活性之二-醯胺化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
ES2328601T3 (es) * 2004-06-28 2009-11-16 Bayer Schering Pharma Ag Pirimidinas 4,6-disustituidas y su uso como inhibidores de proteina cinasa.
MX2009010050A (es) * 2007-03-23 2009-10-12 Amgen Inc Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
WO2009081105A2 (en) * 2007-12-21 2009-07-02 Ucb Pharma S.A. Quinoxaline and quinoline derivatives as kinase inhibitors
EP2365810A2 (en) * 2008-12-04 2011-09-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
CA2781865A1 (en) * 2009-06-25 2010-12-29 Amgen Inc. Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
US8633313B2 (en) * 2009-12-18 2014-01-21 Amgen Inc. Heterocyclic compounds and their uses
JP2013533884A (ja) * 2010-07-02 2013-08-29 アムジエン・インコーポレーテツド Pi3k活性阻害剤としての複素環化合物およびそれらの使用
WO2013152150A1 (en) * 2012-04-04 2013-10-10 Amgen Inc. Heterocyclic compounds and their uses

Also Published As

Publication number Publication date
AP2014007979A0 (en) 2014-09-30
US8716290B2 (en) 2014-05-06
US8835432B2 (en) 2014-09-16
EP2834231B1 (en) 2016-03-30
US20130267524A1 (en) 2013-10-10
RS54716B1 (sr) 2016-08-31
PH12014502246A1 (en) 2014-12-15
AU2013243506A1 (en) 2014-10-09
AP3611A (en) 2016-02-29
ZA201407037B (en) 2015-11-25
HRP20160352T1 (hr) 2016-05-06
KR20140139547A (ko) 2014-12-05
CA2869413A1 (en) 2013-10-10
MX2014011970A (es) 2015-05-12
ES2577109T3 (es) 2016-07-13
DK2834231T3 (en) 2016-04-18
CL2014002686A1 (es) 2015-05-08
SMT201600211B (it) 2016-08-31
EA201491823A1 (ru) 2015-01-30
IL234822A0 (en) 2014-12-31
TN2014000412A1 (en) 2015-12-21
SI2834231T1 (sl) 2016-09-30
MA37472A1 (fr) 2016-09-30
WO2013152150A1 (en) 2013-10-10
HUE028762T2 (en) 2016-12-28
EP2834231A1 (en) 2015-02-11
PE20142457A1 (es) 2015-02-07
ME02473B (me) 2017-02-20
CN104395305A (zh) 2015-03-04
CY1117487T1 (el) 2017-04-26
US20140206694A1 (en) 2014-07-24
CO7091181A2 (es) 2014-10-21
PL2834231T3 (pl) 2016-07-29
JP2015512451A (ja) 2015-04-27
SG11201406316VA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
CR11053A (es) Compuestos heterociclicos y sus usos
CL2024001474A1 (es) Compuestos derivados de heterociclos sustituidos, activadores akt3; composición farmacéutica; y uso
UY33304A (es) Compuestos heterocíclicos y sus usos
CL2017000372A1 (es) Composiciones novedosas, usos y métodos para hacerlas.
EA201270051A1 (ru) Гетероциклические соединения и их применения
PH12018500718A1 (en) Compounds useful as modulators of trpm8
DK3280799T3 (da) Produktion af adeno-associerede vektorer i stor størrelse
NI201500117A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos.
MX2015008766A (es) Compuestos cbd fluorados, composiciones y usos de los mismos.
MX2015012736A (es) 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas.
MA44703A (fr) Compositions liquides à libération prolongée de guanfacine
EP3484468A4 (en) SELF-SMALLING COMPOSITIONS OF CANNABINOIDS
MX2016004461A (es) Analogos de glucagon acilados.
GB2524616B (en) Inter-architecture compatability module to allow code module of one architecture to use library module of another architecture
CL2017000113A1 (es) Mutagénesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las mieloide d tipo 1 (trem-1) para reducir la viscocidad
MX2020001361A (es) Compuestos nuevos como moduladores de ror gamma.
MX347514B (es) Anticuerpos anti-receptores tipo inmunoglobulina citoliticos (kir) para el tratamiento de trastornos inflamatorios.
CL2016001579A1 (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos.
IL243988A0 (en) Combination formulation of two antiviral compounds
CL2018003409A1 (es) Uso de indazoles 2-sustituidos para el tratamiento y la profilaxis de trastornos autoinmunes.
GT201500047A (es) Composiciones, biodegradables, metodos y usos de los mismos
CL2016002281A1 (es) Anticuerpos de il-21
CL2016002615A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo y su uso contra el dolor, accidente cerebrovascular, transtornos anímicos, epilepsia, esquizofrenia y trastornos neurodegenerativos.
CU20170018A7 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
EA201691002A1 (ru) Бициклические гетероарильные аналоги индола, подходящие в качестве модуляторов ror гамма